Generic Name and Formulations:
Anthralin 1.2% (microcrystalline encapsulated); rapid-release cream.
Indications for ZITHRANOL-RR:
Stable plaque psoriasis.
Initially apply once daily (5–15 minutes contact time) for at least one week; may increase contact time to 30 minutes before washing off. Individualize. For skin: use sparingly. For scalp: wash and rinse hair; apply cream while hair is damp; may repeat treatment on alternate days.
Acute or actively inflamed psoriatic eruptions.
Avoid eyes, mucous membranes. Apply cautiously on the face or intertriginous skin areas. Discontinue if sensitization or excessive irritation develops. May stain fabrics; avoid. Pregnancy (Cat.C). Nursing mothers.
Possible contact allergic reactions, discolored hair or fingernails.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Ivacaftor Improves Insulin Secretion in Children With Cystic Fibrosis
- Genetic Testing Recommended for Familial Hypercholesterolemia
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry